Incyte presented preliminary results from a study of an investigational agent that targets calreticulin-mutant myelofibrosis, showing meaningful spleen responses and symptom improvements in patients with advanced disease. The data were disclosed at ASH and reported to be encouraging for an early-stage program. The program is strategically important as Jakafi (ruxolitinib) faces patent expiration in 2028 and Incyte seeks new-category drugs to sustain its hematology portfolio. Company statements and ASH abstracts framed the results as supporting further development. Researchers cautioned the data are preliminary and will need confirmation in larger randomized trials to establish clinical benefit and competitive positioning against established JAK inhibitors and emerging agents.